Hormone Responsive Breast Cancer and BRCA1 Mutation: Mechanism, Regulation and Iron-mediated Effects

Author(s): Abdulrazzaq N. Zghair, Rohit Sharma, Anil K. Sharma

Journal Name: Current Pharmaceutical Biotechnology

Volume 15 , Issue 12 , 2014

Become EABM
Become Reviewer
Call for Editor


Breast cancer is a prominent cause of mortality in women worldwide, with about 2/3rd cases linked to hormone mediated malignancy itself. A hormone receptor positive breast cancer represents cells showing rigorous proliferation upon hormonal exposure. BRCA1 is the predominant marker gene responsible for estrogen regulation. However increased exposure to estrogen is not the sole cause for this abnormality as there is no significant alteration reported in breast tissue estrogen levels. Iron metabolism has also been shown to be frequently altered in breast cancer with considerably higher iron in post menstrual women. In fact estrogen and iron have been implicated to exert synergistic effects on cellular proliferation in BRCA1 linked hormone responsive breast cancer. Thus establishing a link between estrogen and iron metabolism has a great prognostic value in predicting clinical outcome in BRCA1 linked hormone responsive breast cancer patients. Since the time immemorial Iron chelators have been implicated in combating iron dysregulation especially in breast cancer. We summarize here in this review the recent advancements in the area of iron chelation therapy delineating the role of iron in hormone receptor positive Breast cancer.

Keywords: Breast cancer, estrogen, hormone, iron chelation, metabolism.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [1113 - 1124]
Pages: 12
DOI: 10.2174/1389201015666141126120725
Price: $65

Article Metrics

PDF: 36